Grifols (GRFS) EBT Margin Growth (3y) (2013 - 2020)
Grifols (GRFS) EBT Margin Growth (3y) (2013 - 2020) Analysis & Trends
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | -265.00 |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 636.00 |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 3,137.00 |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 625.00 |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -10.00 |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 443.00 |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -15,548.00 |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -6,936.00 |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -2,347.00 |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 217.00 |
| Dec 31, 2019 | 1,387.00 |
| Mar 31, 2019 | -2,371.00 |
| Dec 31, 2018 | 2,053.00 |
| Jun 30, 2018 | 24.00 |
| Mar 31, 2018 | -853.00 |
| Dec 31, 2017 | 3,083.00 |
| Jun 30, 2017 | 2,522.00 |
| Mar 31, 2017 | -1,080.00 |
| Dec 31, 2016 | 105.00 |
| Sep 30, 2016 | 512.00 |
| Jun 30, 2016 | 292.00 |
| Mar 31, 2016 | 1,773.00 |
| Dec 31, 2015 | -261.00 |
| Sep 30, 2015 | 1,040.00 |
| Jun 30, 2015 | 801.00 |
| Mar 31, 2015 | 1,059.00 |
| Dec 31, 2014 | -1,582.00 |
| Sep 30, 2014 | 1,025.00 |
| Jun 30, 2014 | 551.00 |